VALIANTLAB

Valiant Laboratories Limited

· Pharma & Health
₹ CrorePeersALBERTDAVDHALEOSLABSZIMLABMEDICOMEDICAMEQANUHPHRAHCLWANBURY
Comp Set
In ₹ Crore except Per Share
Latest Annual
VALIANTLAB
FY26
ALBERTDAVD
FY26
HALEOSLABS
FY26
ZIMLAB
FY26
Peer
Median
Valuation — at last close
P/E25.32×115.29×70.31×
P/B1.24×1.91×2.48×1.91×
EV/EBITDA52.73×12.22×27.72×27.72×
Market Cap₹485 Cr₹438 Cr₹734 Cr₹485 Cr
Growth
Revenue CAGR 3Y-0.78%1.89%-2.06%-0.78%
Revenue CAGR 5Y6.16%4.68%5.42%
Net Income CAGR 3Y16.09%-37.95%-10.93%
Revenue YoY (latest Q)146.22%43.60%-11.59%31.25%31.25% +368%
Net Income YoY (latest Q)1058.93%303.12%-58.00%-114.25%-58.00% +1926%
Profitability
EBITDA Margin2.69%1.64%13.38%8.02%8.02% -66%
Net Income Margin-1.38%-0.45%5.33%1.56%1.56% -188%
Return on Common Equity-1.05%-0.38%7.54%1.97%1.97% -153%
Return on Capital Employed0.10%-1.06%9.80%2.87%2.87% -97%
Return on Assets-0.70%-0.29%3.92%1.08%1.08% -165%
Credit & Quality
Total Debt/Equity0.14×0.07×0.47×0.42×0.42× -67%
Interest Coverage0.18×-1.63×4.53×0.76×0.76× -76%
Scale — latest FY
Revenue / Total Income₹237 Cr₹334 Cr₹334 Cr₹374 Cr₹334 Cr -29%
Net Income−₹3.3 Cr−₹1.5 Cr₹17.8 Cr₹5.8 Cr₹5.8 Cr -156%
Total Assets₹464 Cr₹519 Cr₹454 Cr₹539 Cr₹519 Cr -11%
EPS₹-0.51₹-2.62₹57.26₹1.19₹1.19 -143%
Book Value per Share₹57.24₹686.04₹759.29₹55.36₹686.04 -92%
◆ best value in the comp set per metric · Δ = subject vs median of the other companies.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.